Recurrence of hepatitis C infection: Where are we now?

被引：27

作者：

Charlton, M ^{[1
]}

机构：

[1] Mayo Clin & Mayo Fdn, Transplant Ctr, Dept Gastroenterol & Hepatol, Rochester, MN 55905 USA

来源：

LIVER TRANSPLANTATION | 2005年 / 11卷 / 11期

关键词：

D O I：

10.1002/lt.20597

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1. Hepatitis C-associated liver failure is the most common indication for liver transplantation, and approximately 10% of HCV-infected recipients will die or lose their allograft secondary to recurrent HCV infection. 2. Risk factors associated with histological recurrence of HCV include donor (age, fat content, ischemic time, and living donor), recipient (age and non-Caucasian race), clinical (rejection and CMV), and viral (viral load and quasispecies). 3. Treatment of recipients with histological recurrence is with pegylated IFN (+/- ribavirin). The role of hepatitis C immunoglobulin in the management of postransplant HCV is still evolving.

引用

页码：S57 / S62

页数：6

共 14 条

[1] Epoetin alfa maintains ribavirin dose in HCV-infected patients: A prospective, double-blind, randomized controlled study [J].

Afdhal, NH ;

Dieterich, DT ;

Pockros, PJ ;

Schiff, ER ;

Shiffman, ML ;

Sulkowski, MS ;

Wright, T ;

Younossi, Z ;

Goon, BL ;

Tang, KL ;

Bowers, PJ .

GASTROENTEROLOGY, 2004, 126 (05) :1302-1311

[2] HCV-related fibrosis progression following liver transplantation:: increase in recent years [J].

Berenguer, M ;

Ferrell, L ;

Watson, J ;

Prieto, M ;

Kim, M ;

Rayón, M ;

Córdoba, J ;

Herola, A ;

Ascher, N ;

Mir, J ;

Berenguer, J ;

Wright, TL .

JOURNAL OF HEPATOLOGY, 2000, 32 (04) :673-684

[3] Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C [J].

Burak, KW ;

Kremers, WK ;

Batts, KP ;

Wiesner, RH ;

Rosen, CB ;

Razonable, RR ;

Paya, CV ;

Charlton, MR .

LIVER TRANSPLANTATION, 2002, 8 (04) :362-369

[4] Peginterferon alfa-2a for hepatitis C after liver transplantation: Two randomized, controlled trials [J].

Chalasani, N ;

Manzarbeitia, C ;

Ferenci, P ;

Vogel, W ;

Fontana, RJ ;

Voigt, M ;

Riely, C ;

Martin, P ;

Teperman, L ;

Jiao, J ;

Lopez-Talavera, JC .

HEPATOLOGY, 2005, 41 (02) :289-298

[5] Predictors of patient and graft survival following liver transplantation for hepatitis C [J].

Charlton, M ;

Seaberg, E ;

Wiesner, R ;

Everhart, J ;

Zetterman, R ;

Lake, J ;

Detre, K ;

Hoofnagle, J .

HEPATOLOGY, 1998, 28 (03) :823-830

[6]

Charlton M, 1999, LIVER TRANSPLANT SUR, V5, pS107

[7] A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation [J].

Crippin, JS ;

McCashland, T ;

Terrault, N ;

Sheiner, P ;

Charlton, MR .

LIVER TRANSPLANTATION, 2002, 8 (04) :350-355

[8] Interferon-α and ribavirin for the treatment of recurrent hepatitis C after liver transplantation [J].

de Vera, ME ;

Smallwood, GA ;

Rosado, K ;

Davis, L ;

Martinez, E ;

Sharma, S ;

Stieber, AC ;

Heffron, TG .

TRANSPLANTATION, 2001, 71 (05) :678-686

[9] Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation [J].

Forns, X ;

García-Retortillo, M ;

Serrano, T ;

Feliu, A ;

Suarez, F ;

de la Mata, M ;

García-Valdecasas, JC ;

Navasa, M ;

Rimola, A ;

Rodés, J .

JOURNAL OF HEPATOLOGY, 2003, 39 (03) :389-396

[10] A longitudinal analysis of hepatitis C virus replication following liver transplantation [J].

Gane, EJ ;

Naoumov, NV ;

Qian, KP ;

Mondelli, MU ;

Maertens, G ;

Portmann, BC ;

Lau, JYN ;

Williams, R .

GASTROENTEROLOGY, 1996, 110 (01) :167-177

← 1 2 →